Showing 501 - 520 results of 10,572 for search '"Tumor"', query time: 0.09s Refine Results
  1. 501

    Dilated SE-DenseNet for brain tumor MRI classification by Yuannong Mao, Jiwook Kim, Lena Podina, Mohammad Kohandel

    Published 2025-01-01
    “…This novel approach aims to improve upon state-of-the-art methods of tumor identification. Our model, trained and evaluated on a comprehensive Kaggle brain tumor dataset, demonstrated superior performance over established convolution-based and transformer-based models: ResNet-101, VGG-19, original DenseNet-121, MobileNet-V2, ViT-L/16, and Swin-B across key metrics: F1-score, accuracy, precision, and recall. …”
    Get full text
    Article
  2. 502

    CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors by Olga R. Brook, Eavan Thornton, Mishal Mendiratta-Lala, Anand Mahadevan, Vassilious Raptopoulos, Alexander Brook, Robert Najarian, Robert Sheiman, Bettina Siewert

    Published 2015-01-01
    “…To study radiological response to stereotactic radiotherapy for focal liver tumors. Materials and Methods. In this IRB-approved, HIPAA-compliant study CTs of 68 consecutive patients who underwent stereotactic radiotherapy for liver tumors between 01/2006 and 01/2010 were retrospectively reviewed. …”
    Get full text
    Article
  3. 503
  4. 504
  5. 505

    DIAGNOSTIC COMPETENCE IN BONE TUMORS: INFLUENCE OF ONCO-ORTHOPEDIC TRAINING by Julia Pozzetti Daou, Caio Falk Giannotti, Jairo Greco Garcia, Marcelo de Toledo Petrilli, Dan Carai Maia Viola, Reynaldo Jesus Garcia Filho

    Published 2025-02-01
    “…Abstract Understanding the nature of musculoskeletal tumors is crucial for appropriate management and to secure a favorable prognosis. …”
    Get full text
    Article
  6. 506
  7. 507
  8. 508

    Non‐Invasive Tumor‐Naïve Minimal Residual Disease Detection of Liver Cancer by Incorporating Circulating Tumor DNA Features and Alpha‐Fetoprotein: A Prospective Study by Qingqi Ren, Shiyong Li, Guolin Zhong, Yunfei Li, Dao‐Ling Huang, Liangliang Zhang, Yumin Feng, Guanghui Long, Mao Mao

    Published 2024-12-01
    “…Identifying MRD through reliable prognostic biomarkers, such as circulating tumor DNA (ctDNA), could significantly benefit these patients by enabling timely intervention and improved outcomes. …”
    Get full text
    Article
  9. 509
  10. 510

    Synthesis and Characterization of Theranostic Poly(HPMA)-c(RGDyK)-DOTA-Cu Copolymer Targeting Tumor Angiogenesis: Tumor Localization Visualized by Positron Emission Tomography by Jianchao Yuan, Haiyuan Zhang, Harpreet Kaur, David Oupicky, Fangyu Peng

    Published 2013-05-01
    “…Poly(HPMA)-c(RGDyK)-DOTA- 64 Cu copolymers were synthesized and characterized for tumor localization in vivo as a theranostic scaffold for cancer imaging and anticancer drug delivery targeting tumor angiogenesis. …”
    Get full text
    Article
  11. 511

    Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen by Boya Zhong, Guangyu Ma, Ayako Sato, Osamu Shimozato, Hongdan Liu, Quanhai Li, Masato Shingyoji, Yuji Tada, Koichiro Tatsumi, Hideaki Shimada, Kenzo Hiroshima, Masatoshi Tagawa

    Published 2015-01-01
    “…We examined whether administration of DNA encoding FasL gene enhanced antitumor effects in mice that were vaccinated with DNA expressing a putative tumor antigen gene, β-galactosidase (β-gal). Growth of β-gal-positive Colon 26 tumors was retarded in the syngeneic mice immunized with β-gal and FasL DNA compared with those vaccinated with β-gal or FasL DNA. …”
    Get full text
    Article
  12. 512
  13. 513
  14. 514

    Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types by Jeffrey S Ross, Richard S P Huang, Jake G Maule, Lani K Clinton, Ryon P Graf, Jinpeng Xiao, Geoffrey R Oxnard

    Published 2022-10-01
    “…Here we present 22C3, 28-8, and SP142 analysis of 418 tumor specimens encountered in routine clinical practice.Methods All specimens were tested with 22C3, 28-8, and SP142 assays following the manufacturer’s established staining protocols.Results The same PD-L1 status (defined as tumor cell expression (TC) scores with all three assays ≥1% or all <1%) was observed in 60.0% (251/418) tumor specimens (45.9% (192/418) were triple negative and 14.1% (59/418) were triple positive). …”
    Get full text
    Article
  15. 515
  16. 516
  17. 517
  18. 518
  19. 519
  20. 520